Summary & Overview
HCPCS Q4121: Theraskin Skin Substitute, Per Square Centimeter
HCPCS Level II code Q4121 designates Theraskin billed per square centimeter as an add-on skin substitute product to be listed separately in addition to a primary procedure. As a product-specific code, it matters nationally because it standardizes reporting for biologic skin dressings used in wound care and surgical reconstruction, supporting clearer claims adjudication and supply tracking across payers and sites of service.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for Theraskin use, common sites of service where the product is supplied, and the implications of using an add-on HCPCS product code for billing workflows. The publication also summarizes expected content areas for payer coverage differences, typical documentation elements tied to skin substitute use, and where to expect policy or reimbursement variability.
This summary is intended for a national audience of billing professionals, revenue cycle managers, and clinicians involved in wound care or surgical procedures who need a clear reference to the HCPCS Level II code, its clinical application, and the practical billing considerations when Theraskin is supplied in addition to a primary procedure.
Billing Code Overview
HCPCS Level II code Q4121 describes Theraskin, billed per square centimeter as an add-on itemized product to be listed separately in addition to a primary procedure. The code represents a biologic skin substitute product applied to wounds or other cutaneous defects and is typically supplied and accounted for by the performing facility or provider.
Service Type: Skin substitute / biologic dressing product
Typical Site of Service: Hospital outpatient departments, ambulatory surgery centers, wound care clinics, and other procedural settings where a primary surgical or wound management procedure is performed.
Clinical & Coding Specifications
Clinical Context
A patient with a full-thickness skin defect following excision of a skin cancer or traumatic injury undergoes surgical wound bed preparation and closure planning. The surgeon determines that a biologic skin substitute product, billed as Q4121 (Theraskin, per square centimeter, add-on), will be applied to the wound to promote healing and provide a biologic matrix adjunct to primary repair. Typical workflow: preoperative evaluation documents diagnosis and indication for skin substitute; debridement and hemostasis are performed in the operating room or procedure suite; the primary procedure (for example, excision and layered closure or graft placement) is completed; the clinician measures the square centimeters of Theraskin used and documents product lot numbers and units applied; Q4121 is appended to the claim as an add-on supply code in addition to the primary procedure code; appropriate modifiers are attached as indicated by the encounter (e.g., laterality, multiple surgeons, discontinued service, or patient condition). Typical site of service is an ambulatory surgery center, hospital outpatient department, or office-based procedure suite depending on complexity and anesthesia. Typical patient scenario: an adult undergoing Mohs tumor excision with resulting dermal defect where the surgeon applies Q4121 as an adjunctive biologic dressing to support granulation and reduce graft failure risk; documentation includes square centimeters applied, product identifiers, and correlation to the primary surgical procedure.
Coding Specifications
| Modifier | Description | When to Use |
|---|